2025-07-11 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data.  The report is in English and includes key figures followed by a brief analysis.

**Johnson & Johnson (JNJ) Stock Analysis**

Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.

**1. Performance vs. S&P 500 (VOO)**

*   **JNJ Cumulative Return:** 16.17%
*   **VOO Cumulative Return:** 96.17%
*   **Absolute Spread:** -80.4 (JNJ underperforms VOO by a significant margin)
*   **Relative Spread:** 2.5  (Indicates JNJ's underperformance is near the lower end of its historical range relative to the S&P 500)

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
| :----------- | :------ | :------ | :----- | :--- | :------ |
| 2015-2017  | 28.0%   | 56.1% | -1.0%  | -0.0 | 336.2  |
| 2016-2018  | 8.0%    | 56.6% | -10.0% | 0.0  | 310.5  |
| 2017-2019  | 18.0%   | 56.6% | -12.0% | 0.7  | 351.0  |
| 2018-2020  | 12.0%   | 59.2% | -8.0%  | 0.3  | 378.7  |
| 2019-2021  | 32.0%   | 59.6% | -16.0% | 0.2  | 411.6  |
| 2020-2022  | 7.0%    | 61.4% | 5.0%   | 0.2  | 425.0  |
| 2021-2023  | -15.0%  | 61.4% | -33.0% | 0.4  | 377.1  |
| 2022-2024  | -35.0%  | 61.4% | -61.0% | 0.3  | 348.0  |
| 2023-2025  | -11.0%  | 70.1% | -59.0% | 0.2  | 379.4  |

*   **Analysis:** The table indicates JNJ has significantly underperformed the market. The negative Alpha values, particularly in recent years, highlight this. Beta values are relatively low, suggesting JNJ is less volatile than the overall market.  The MDD (Maximum Drawdown) values are relatively high, indicating potential for significant losses.

**2. Recent Stock Price Movement**

*   **Current Price:** 157.69
*   **Previous Close:** 156.28
*   **Change:** 0.9
*   **5-day Moving Average:** 156.15
*   **20-day Moving Average:** 154.12
*   **60-day Moving Average:** 154.14

*   **Analysis:** The stock is trading above its 5, 20, and 60-day moving averages, suggesting a short-term upward trend. The recent price increase, as indicated by the positive change and current price being above the moving averages, suggests positive momentum.

**3. Market Risk Indicator and Other Indicators**

*   **MRI:** 0.3373 (Low Risk)
*   **RSI:** 80.05 (Overbought)
*   **PPO:** 0.3156
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Divergence Change:** -0.6 (Negative - Short-term decline)
*   **Expected Return:** -1170.7% (Significantly negative, indicating substantial underperformance compared to the S&P 500 over a 2+ year investment horizon)

*   **Analysis:** The MRI suggests a low-risk environment. However, the RSI is in overbought territory, potentially indicating a price correction is due.  The Hybrid Signal recommends a cautious approach.  The significantly negative expected return is a major concern, suggesting JNJ is projected to severely underperform the S&P 500. The negative change in relative divergence reinforces the possibility of a short-term decline. The significant 'change' value (0.9) is reflected in RSI(Overbought).

**4. Recent News & Significant Events**

*   **2025-07-09:** Major business developments, regulatory changes, or market events.
*   **2025-07-11:** Analyst discussions regarding recent performance and outlook.
*   **2025-07-07:** Stock volatility influenced by recent news, earnings, or executive actions.
*   **2025-07-10:** Market experts highlighting risks and opportunities.

*   **Analysis:** Recent news suggests volatility and active market discussion surrounding JNJ, indicating the stock is subject to both potential opportunities and risks.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
| :--------- | :---- | :-------- |
| 2025-04-23 | 4.57  | 21.89 B$ |
| 2024-10-23 | 1.12  | 22.47 B$ |
| 2024-07-25 | 1.95  | 22.45 B$ |
| 2024-05-01 | 1.35  | 21.38 B$ |
| 2025-04-23 | 1.35  | 21.38 B$ |

*   **Analysis:** The data shows fluctuating EPS and revenue figures over the last few quarters. The recent EPS figure of 4.57 stands out, while revenue has been relatively stable. The duplicated date may be error, so this needs to be confirmed.

**6. Financial Information**

Revenue and Profitability:

| Quarter      | Revenue    | Profit Margin |
| :----------- | :--------- | :------------ |
| 2025-03-31 | $21.89B  | 66.40%        |
| 2024-12-31 | $22.52B  | 68.35%        |
| 2024-09-30 | $22.47B  | 69.01%        |
| 2024-06-30 | $22.45B  | 69.40%        |
| 2024-03-31 | $21.38B  | 69.55%        |

Capital and Profitability:

| Quarter      | Equity     | ROE      |
| :----------- | :--------- | :------- |
| 2025-03-31 | $78.11B  | 14.08%  |
| 2024-12-31 | $71.49B  | 4.80%   |
| 2024-09-30 | $70.16B  | 3.84%   |
| 2024-06-30 | $71.54B  | 6.55%   |
| 2024-03-31 | $70.02B  | 4.65%   |

*   **Analysis:** Revenue has been relatively stable, although there is some decrease recently. Profit margins have remained strong but decreased. The most recent quarter shows a substantial increase in both equity and ROE, but this may be anomaly.

**7. Overall Analysis & Summary**

Based on the provided data, Johnson & Johnson (JNJ) presents a mixed picture:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500.
*   **Recent Momentum:** There's short-term positive price momentum, but the RSI indicates it might be overbought.
*   **Low Risk (MRI):** Overall market risk appears low.
*   **Concerning Expected Returns:** The severely negative expected return is a major red flag, suggesting significant underperformance relative to the S&P 500.
*   **Recent News:** Recent news highlights volatility and market attention.
*   **Financial Health:**  Revenue and profit margins remain strong but decreased over time.

**Conclusion:**

While JNJ exhibits financial stability and short-term positive price movement, the significant underperformance compared to the S&P 500 and the negative expected returns warrant caution. Investors should carefully consider the reasons behind this underperformance and the potential for future growth before making investment decisions. Further investigation into JNJ's recent business developments, regulatory changes, and market events (as highlighted in the news) is crucial. The overbought RSI suggests potential for a pullback. The conflicting signal from the MRI (low risk) and expected return (significant underperformance) requires further analysis.
